House Democrats And Price Negotiation: Slogan Is Unifying, But Policy Is Tougher
The most important thing to know about a draft version of the House Democratic leadership’s proposed drug price negotiation plan is that it is still just a draft – not the draft – much less a bill that could pass the Democratic controlled House, to say nothing of the GOP controlled Senate.
You may also be interested in...
The debate over price 'negotiation' in the US has taken a turn for the worse for innovator pharma companies. The Democratic party seems eager to plow forward no matter what the impact is on innovation – and some patient advocates are surprisingly eager to cheer them along.
Pelosi is moving forward with a draconian plan to limit US prices to an international benchmark. For now, the “bill” is a three-page outline subject to considerable legislative drafting – and so extreme as to rule out bipartisan compromise for the time being.
If nothing else, the purported draft may be a preview of what Democrats might do if they prevail in 2020. Proposal calls for HHS price negotiation, international reference pricing, price inflation rebates and structural Medicare Part D changes.